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Several studies have found that the loss of a child is associated with psychiatric health prob-
lems, yet few studies examined whether child loss influences psychotropic medication use.
This study examined short- and long-term use of psychotropic medication, both before and
after the death of a child, and its potential effect modifiers.
Methodology/Principal findings
A random sample of 205,456 parents, including 902 bereaved parents, were selected from
a Finnish total population registry. The analyses were based on linear regressions using
generalised estimation equations (GEE) and adjusted for sociodemographic factors. Annual
psychotropic use was defined as having purchased prescribed psychotropic medication
between 1996 and2012. Bereaved parents were followed for four years prior to and up to
four years after the death of their child. An increase in the use of antidepressants and anxio-
lytics was found in parents following their loss. The highest percentage of use was found
around one year after bereavement, followed by a steady decrease although this remained
higher than the level of use among non-bereaved four years after the death. Between 20–
25% of bereaved mothers and 10–15% of bereaved fathers used antidepressants or anxio-
lytics one year after bereavement while the corresponding number in non-bereaved was
5–10%. An increase in psychotropic medication was also found several years before the dis-
ease-related loss of a child.
Conclusions/Significance
The use of psychotropic medication is markedly higher among parents after losing a child.
Patterns of use leading up to and following the death of a child should be further examined
in relation to clinical risk factors so as to identify at risk populations.
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Introduction
In high income countries, the loss of a child is often rare and unexpected. Hence, it is consid-
ered to be one of the most stressful and traumatic life events a person may encounter, espe-
cially when the event occurs early in the child’s and parent’s lives [1,2]. While previous studies
have found that the loss of a child has significant consequences for parental mental health in
the period immediately following their death [3], few studies have examined how this loss
impacts the use of psychotropic medication both before and after the event.
A review by Stroebe et al. suggests that bereavement–such as the death of a spouse or child–
is associated with several psychological symptoms and illnesses [3,4]. Individual reactions to
bereavement include suicidal ideation [5–7]; insomnia [8]; depression, anxiety and depression
[9–11]; somatic symptoms; social dysfunction [12]; psychiatric hospitalization [13] and suicide
[14]. These reactions are most likely to arise in the early stages of bereavement [3,15–17]. They
may also be strongly related to the use of psychotropic medication.
Previous evidence on bereavement and the consequent use of psychotropic medication is
sparse, and to our knowledge few studies have examined child loss and psychotropic medica-
tion use specifically, especially prior to bereavement. Lacasse and Cacciatore found that 37.5%
of bereaved parents who suffered the perinatal/neonatal death of a child were prescribed medi-
cation–primarily antidepressants–to help to deal with their loss [18]. Wall-Wieler et al. found
that elevated rates of depression, anxiety and psychotropic medication use after the death of an
infant end within 1 year of the child’s death [19]. Other studies have found that the loss of a
spouse or partner is associated with an increased use of anti-depressive medication. For
instance, Möller et al. showed that prescribed psychotropic medication was more common
among widowed individuals than married partners, especially among those recently bereaved
[20]. A study on cohabitees of cancer patients also found that exposed individuals were more
likely to receive a prescription for antidepressant or hypnotic medication both before and after
the death of their spouse or partner [21]. Finally, Oksuzyan et al. found that the average daily
use of all-cause and major system-specific medications increased from one year before to five
years after their spouse’s death, with no sex-specific patterns in the trajectories of medication
use [22]. We thus hypothesizse that the death of child is also associated with increased psycho-
tropic use around the time of death.
Bereaved individuals often experience acute suffering, particularly in the initial stages of
loss [10,23,24]. Some research indicates that grief following child loss usually persists for the
remainder of a parent’s life [10,25], while other studies support the shorter-term consequences
of child bereavement [9,24]. This variability may reflect differences in the way bereavement
outcomes are measured. For instance, previous studies have indicated an increased risk of
mortality in bereaved mothers and parents in general, particularly with regards to external
causes of death (i.e. suicide, homicide or accident) [26]. However, the empirical evidence on
whether child bereavement contributes to psychotropic medication use is sparse, so we cannot
extrapolate such patterns to the use of psychotropic medication without further investigation.
From a health policy perspective, the study of bereavement and use of psychotropic medica-
tion is crucial. Although the use of psychotropic medication may be considered an indicator of
depression and mental health problems, it may also paradoxically be seen as a means to avoid
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more severe long-term outcomes, such as psychiatric illness and suicide following bereave-
ment [13,14], both in general and for child loss in particular. The potential harms of psycho-
tropic medication use in relation to bereavement are also unknown [27]. It is therefore highly
important to study the duration of psychotropic medication use following child death.
Our aim is to complement the literature on the health effects of bereavement by studying
parents’ use of psychotropic medication (including antidepressants, anxiolytics and antipsy-
chotics) both before and after the death of a child, using nationally representative population
registry data from Finland. These data are unique as they are not prone to non-participation
bias during study recruitment, loss to follow-up or reporting bias on mental health. We postu-
late that the effect of a child’s death on the use of psychotropic medication will depend on the
time before and after the death, the parent’s sex, the nature of the child’s death (disease or
external cause) and the age of the child at the time of death.
Methods
The 2000 Family Study includes a 20% random sample of Finnish households with at least one
child aged 0–14 years at baseline in the end of 2000, with individual-level information on all
household members (total n = 415,000) supplemented with a 20% random sample of 0–14-
year-olds not living in private households (n = 1,600). In addition, all non-resident biological
and adoptive parents (n = 28,000) of the 0–14-year-olds in the two samples were included. The
data were drawn from population registers at Statistics Finland, with follow-up on mortality
data until the end of 2012, and extensive measurement of sociodemographic factors for the
period from 1970 to 2012 on all study subjects. Using unique personal identification numbers,
these data were linked with complete prescription register information from the Social Insur-
ance Institution of Finland on medication purchases. The prescription register includes data
on the date of purchase and type of medication according to the Anatomical Therapeutic
Chemical (ATC) classification system. The register holders have approved the use of their data
for scientific research. The study has also been approved by Statistics Finland Board of Ethics
(Permission TK-53-525-11). Due to data protection regulations of the administrative sources
providing the register data, the authors do not have the permission to make the data available
to third parties. Interested researchers have the possibility to obtain data access directly by con-
tacting Statistics Finland (tutkijapalvelut@stat.fi, +358917342758) and the Social Insurance
Institution (toimistopalvelut@kela.fi, +358206341364).
For the purposes of this study, we defined children as those who were aged 0–14 years at
the end of 2000, regardless of their age and family status at the time of death in the 2001–2011
follow-up period. Altogether, there were 205,456 parents in the sample, including 474 mothers
and 428 fathers who lost a child. Biological parents were primarily followed-up for the use of
psychotropic medicine, regardless of whether they were living with their children or not. How-
ever, in case information on the biological parent was missing (1,557 children), we included
the resident adoptive parent in the data. 10 mothers and 13 fathers died during the follow-up,
and less than one percent of parents migrated in any given year of follow-up. Those dying
were censored at the date of death and those migrating at the end of the year before migration.
There were 209 stepmothers and 764 stepfathers included in the dataset for children who
did not have information on their biological mother/father. Of these, four mothers and 20
fathers experienced the death of a child. Adjustment for whether a parent was biological or
adoptive had very little effect on the outcomes (analyses available upon request). In the few
cases that parent lost two children (9 mothers and 9 fathers), we analyzed the death of the
youngest child (sensitivity analyses indicate that excluding these cases had little effect on our
results; analyses available upon request). We also studied the nature of the child’s death and its
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effect on psychotropic use. We categorized deaths accompanied by the ICD-10 codes A00-R99
and X45 as disease-related, as they cover all diseases as well as accidental poisoning by alcohol.
The remainder of the deaths were considered external, including accidents, suicides, assaults
and sequelae of assaults, and all other external causes.
Annual psychotropic use was defined as having purchased prescribed psychotropic medica-
tion between 1996 and 2012. We followed medication use on the basis of exact day of purchase
for four years (i.e. four 12 month periods) before the exact date of death a child, and between
one to four years after their death. S1 Fig shows the structure of the data by period, one-year
study cohorts, and year. For the comparison group of parents who did not lose a child, a refer-
ence date in the period 2001–2012 was randomized and medication use was followed around
this date. This study covered the use of psycholeptics and psychoanaleptics (ATC-codes N05 &
N06), excluding medication for dementia (N06D). These were further divided into three
groups: (1) antidepressants (N06A and N06CA01), but excluding tricyclic medication
(N06AA, except N06AA22 and N06AA24) which is commonly used for non-psychiatric indi-
cations [28,29]; (2) anxiolytics, sedatives and hypnotics (N05B and N05C); and (3) other psy-
chotropic medication (N05A, N06B, and N06C). In the latter group the vast majority of
prescriptions were antipsychotic. These three are the most common classes of psychotropic
medication used for the treatment of major depressive disorder [30]. The setting for prescrip-
tion and purchase of psychotropic medication in Finland has been described in more detail
elsewhere [30]. Table 1 shows the proportion of parents with purchases of different types of
psychotropic medication.
We used several socio-demographic factors as control variables and potential effect modifi-
ers. The models were adjusted for age, parental education (basic schooling, secondary and ter-
tiary education) and for the number of children in the family aged 7 or under and 18 and
under. These were all measured at the end of the year preceding the death of a child for
bereaved parents, or the reference date for parents who did not lose a child. Furthermore, the
models were adjusted for parental living arrangements (living alone, married with/without
children, single mothers/fathers, cohabiting with children, unknown), occupation-based social
class (10 categories), household income per consumption unit and hospital district, all as
yearly time-varying variables. Furthermore, the models where mothers and fathers were stud-
ied together were adjusted for sex. S1 Table shows the distribution of the covariates adjusted
for in the models by whether a parent lost a child or not. Fig 1 shows the measurement points
for different variables with an example of a death date or reference date taking place in 2005.
Table 1. Total number of parents and number of parents whose child died and the proportion with purchases of psychotropic medication in 1997–2012.
Total number of parents Antidepressant Anxiolytics Antipsychotics
medication1 (%) medication2 (%) medication3 (%)
Mothers 104 047 9,9 6,5 2,1
Farthers 101 409 5,4 5,1 1,6
Total 205 456 7,7 5,8 1,9
Number of parents whose child died
Mothers 474 18,3 14,9 4
Farthers 428 9,6 9,1 2
Total 902 14 12,1 3,1
1 ATC-codes N06A and N06CA01 (excluding tricyclic medication N06AA, except N06AA22 and N06AA24).
2 ATC-codes N05B and N05C.
3 ATC-codes N05A, N06B, and N06C.
https://doi.org/10.1371/journal.pone.0195500.t001
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The analyses of psychotropic medication use were based on linear regressions using gener-
alised estimation equations (GEE), with the results shown as the prevalence of use of psycho-
tropic medication. The repeated measures of medication use per subject are highly dependent
on each other, and GEE accounts for this interdependence between repeated within-subject
measurements by assigning them a correlation structure [31]. An autoregressive correlation
structure was chosen on the assumption that the correlation is stronger between observations
that are closer to each other in time.
Associations between the death of a child and the prevalence of psychotropic medication
use were assessed by examining interactions between parental bereavement status and the
study year, i.e. assessing psychotropic medication use in the years before and after the death of
child or reference date, and by plotting the model-based estimates of medication use as graphi-
cal trajectories.
Results
We found a marked increase in the use of antidepressants and anxiolytics in mothers and
fathers following the death of a child, with the highest percentage of medication use around
one year after their child’s death (Fig 2). Even though medication use decreased after this
point, it was still higher than among non-bereaved parents four years after the death. Between
20–25% of bereaved mothers and 10–15% of bereaved fathers used antidepressants or anxiolyt-
ics one year after bereavement, while the corresponding number in non-bereaved parents was
5–10%. The use of anxiolytics was also slightly increased among mothers several years before
the death of a child, but not for fathers.
Furthermore, the use of antipsychotics increased among bereaved mothers in the first two
years following the death of their child. While about 2% of the non-bereaved mothers used
antipsychotics, the corresponding figure was about 5% among bereaved mothers. There were
no differences in the use of antipsychotics among fathers.
Although the level of psychotropic medication use differed by sex, the shape of the trajecto-
ries were similar. In order to have a sufficient number of cases in the analyses covering the
nature of the child’s death, we thus combined the sexes and adjusted for the variable instead
(Fig 3). An increase in psychotropic medication use was found both several years before and
after disease-related deaths. When the cause of death was external, we found no excess in med-
ication use preceding the death of a child but a considerable increase in use during the first
year following the death. The use of antipsychotics was much rarer than antidepressants, and
there was a statistically significant difference in use only between bereaved parents due to
external causes of death and non-bereaved parents.
For the final analyses, we only included those parents who had lost a child. We were inter-
ested in whether the use of psychotropic medication was different among parents whose child
died aged younger or older than 15 years (Fig 4). However, young age at death only moderately
Fig 1. Measurement points for different factors in the study.
https://doi.org/10.1371/journal.pone.0195500.g001
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influenced the use of psychotropic medication in parents, and no systematic patterns were
observed.
Discussion
Summary of the main results
The aim of this study was to study parents’ use of psychotropic medication before and subse-
quent to the death of a young child, using population registry data from Finland. We found a
marked increase in the use of antidepressants and anxiolytics in mothers and fathers following
the death of their child. The highest level of medication use was found around one year after
the child’s death, after which use decreased. Regardless, medication use among bereaved
parents remained higher than among non-bereaved parents four years after the death of a
child or four years after the randomly selected control date, respectively. We also found that
the increase in use of psychotropic medication was somewhat more pronounced among
bereaved mothers than fathers, and for deaths due to external causes rather than disease-
related deaths. Child’s age at death only modestly modified the use of psychotropic medication
in parents. Furthermore, psychotropic medication use increased strongly in the one year
before death when the child had died from a disease.
Interpretation
Our findings are likely to reflect the fact that bereavement gives rise to psychiatric symptoms
and illnesses ranging from social dysfunction and affective symptoms to more severe psychiat-
ric hospitalization and even suicide [3, 5–14]. Thus, the use of psychotropic medication can be
interpreted as a means of coping with underlying psychological and mental health problems
following the traumatic event of a child’s death. However, it is also possible that psychotropic
medication is used to treat normal grief reactions to painful and traumatic events such as child
loss and not merely complicated grief. Our findings also show that the highest level of psycho-
tropic medication use was found in the first year after loss. This is in line with research indicat-
ing that psychiatric health problems are most intense in early bereavement [10,23,24]. The
finding also corresponds to a recent study showing that elevated rates of psychotropic medica-
tion use end within 1 year of the death of an infant child. However, since our results also sug-
gested an increased level in the use of psychotropic medication up to four years after
bereavement (and in some cases even prior to bereavement), it is important to acknowledge
that child loss could lead to potential long-term harmful effects [27]. A longer-term increase
(i.e. after one year) in the use of psychotropic medication was however not found in the afore-
mentioned study on infant death [19]. Thus, other types of bereavement support, such as
counselling, should be considered as an alternative to avoid longer-term psychotropic depen-
dency. Future research should also compare patterns of uncomplicated or normal grief to pat-
terns of complicated grief, specifically in relation to the use of psychotropic medication, so as
to assess the overall benefits and harms of pharmacological treatments. In particular, clinicians
must question whether or not uncomplicated grief is a life situation which can be effectively
treated with medication [32].
Our findings indicate a larger absolute increase in the use of psychotropic medication after
child loss among mothers when compared to fathers. These findings can be interpreted using
Fig 2. Fathers’ and mothers’ use of psychotropic medication (percent with 95% Cis) four years before and after the death of a child by medication type
(antidepressants, anxiolytics and antipsychotics). Adjusted for parental age, calendar year, number of children in the family under the ages of 7–18, health care
district, living arrangements, education, occupation based on social class and household income per consumption unit.
https://doi.org/10.1371/journal.pone.0195500.g002
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theories on social relationship quality and attachment between children and parents.
Throughout the life course, gender-related norms and role expectations tend to foster
greater attachment of children to mothers than to fathers [33,34]. The mother-child rela-
tionship is characterized by more shared values and attitudes, greater affective closeness
and higher stability, e.g. in cases of parental separation, than the father-child relationship
[35]. This may account for the stronger adverse impact of a child’s death on maternal men-
tal health, as well as its consequent increase in use of psychotropic medication. This finding
is supported by previous studies which also suggest more detrimental health consequences
for mothers than fathers following the death of a child [2,26]. However, the larger increase
in women’s use of medication may also be explained by higher overall depression rates and
the increased vulnerability and sensitivity of women to stressful events. Child loss can thus
have a greater impact on the mental health of women and thereby contribute to a higher
increase in the use of psychotropic medication.
The child’s cause of death can have significant implications for the intensity of a parent’s
bereavement symptoms and consequent medication use, which is why we also studied these
consequences by distinguishing between disease-related and external causes of death. In most
cases, child deaths from external causes such as accidents and suicides are unexpected and can
thus have a stronger and more immediate influence on parental wellbeing. This can cause a
more severe and complicated grief process [36] and thereby lead to more frequent and possibly
longer-term use of psychotropic medication. On the other end of the spectrum, diseases gener-
ally take some time to develop and thus death may be experienced with more preparation.
Death from natural causes may be eased through more supportive functions within the health
care system both before and after the death. Furthermore, parents of children with chronic dis-
eases may have more time to come to terms with the approaching death. Accordingly, our
results suggest differing trends of psychotropic medication use between our disease-related
and external cause of death child mortality cohorts.
We also found an increase in psychotropic medication use several years before children’s
deaths from a disease, indicating that parents may use psychotropic medication to cope with
their child’s fatal disease already before the death. Four years prior to a child’s death from a dis-
ease, the level of psychotropic medication use is very similar to that of parents who do not
experience child death. This fact and the absence of the anticipatory effect for more sudden
and unexpected child deaths due to external causes is strong evidence for the causality of the
patterns of psychotropic use that we observe in this study.
Limitations
There were obvious strengths of this study, including the use of a representative sample of the
total Finnish population; a longitudinal follow-up design; and reliable information on pre-
scribed use of psychotropic medication with no loss to follow-up or self-report bias. However,
some limitations should be noted. More detailed individual information is required to uncover
the actual causal mechanisms behind bereaved parents’ use of psychotropic medication. It
would be ideal to access and utilize indicators of parental-child attachment, which could
amplify or suppress the risk for adverse outcomes. Stronger parental-child attachment may
lead to more mental health problems and consequent use of psychotropic medication in
bereaved. Moreover, using pharmaceutical purchases as an indicator of psychotropic
Fig 3. Parental use of psychotropic medication (percent with 95% Cis) four years before and after the death of a child by medication type
(antidepressants, anxiolytics and antipsychotics) and cause of death of a child. Adjusted for parental age and sex, calendar year, number of children under
the ages of 7 and 18, health care district, living arrangements, education, occupation based on social class and household income per consumption unit.
https://doi.org/10.1371/journal.pone.0195500.g003
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medication use could pose some limitations, since purchases do not necessarily reflect the
severity of underlying mental health problems and the need for medication.
Regardless, our outcome measure of choice exhibited some pertinent strengths. First,
accounting for our context, we must acknowledge the role of Finnish medical professionals in
prescribing psychotropic medication to patients. This means that the use of such medication is
dependent on a clinical assessment of the patient’s actual need for treatment [37]. Changes in
the use of such medication are thus likely to denote changes in mental health that are not only
observed by the persons themselves but also have direct implications for the provision of medi-
cal care. In addition, psychotropic medication use is a significant predictor of other adverse
outcomes such as early retirement due to disability [38]. This may have strong implications on
predicting patterns of government aid in other social welfare systems. On a final note, our
findings may be indicative of other contexts and patterns of psychological need around stress-
ful life events. Similar changes in the use of psychotropic medication before and after divorce
have been found in Finnish register-based data as well as in a self-reported trajectory of psy-
chological distress in the UK [39]. Needless to say, these findings should not be generalized
without caution. Further studies on serious illness in children and its effects on the mental
health of parents may provide further validation of our study results.
Conclusions
To our knowledge, few population-based studies beyond ours have examined the use of psy-
chotropic medication in bereaved parents around the death of a child. Given the increase in
use of psychotropic medication among bereaved parents both before and after the death of a
child, our findings indicate that child death can be associated with significant mental distress.
Psychotropic medication may be used as a mean to alleviate these symptoms and avoid more
severe outcomes such as suicide or psychiatric disease. However, our findings also call for a
critical discussion of whether grief, especially uncomplicated grief, is a life situation that should
be treated with medication. The results do provide strong evidence for the general idea that
stressful life events have significant adverse health effects.
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Formal analysis: Netta Mäki.
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